Biogen Inc. (BIIB)

NASDAQ

$225.63

$+7.25

(+3.32%)

After-Hours

Biogen Inc. (BIIB) Live Price Chart

Last updated: ⁦2026-10-09 21:29:40⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Biogen Inc. (BIIB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $225.63, with a market capitalization of $32.82B and a P/E ratio of 38.67. Over the past 52 weeks, its price has ranged from $138.00 to $230.49. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$32.82B
Open	$220.62
Day's High	$480.18
Day's Low	$5.93
Previous Close	$218.43
Volume	663.93K
Average Volume	1.06M
P/E Ratio	38.67
52-Week High	$230.49
52-Week Low	$138.00
Dividend Yield	--
Earnings Date	--

Biogen Inc. (BIIB) After-Hours Stock Price

Biogen Inc. (BIIB) is trading at $224.08 in after-hours trading as of 2026-10-09 21:08:00, up 2.59% ($5.65) from the regular-session close of $218.43.

After-hours trading shows how investors are pricing BIIB after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.

Biogen Inc. (BIIB) 7-Day Stock Price Change

Over the past seven days, Biogen Inc. (BIIB) moved from $225.88 to $225.63, representing a decline of 0.11% ($0.25).

The stock traded between $215.73 and $229.36 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.

The average daily volume was 1.24 million shares, up versus the previous seven-day period, indicating higher trading activity.

BIIB 52-Week Price Position

Position in Range: 94.7%

52W Low$138.00

52W High$230.49

BIIB is currently trading at $225.63, placing it 94.7% of the way from its 52-week low of $138.00 to its 52-week high of $230.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Biogen Inc. (BIIB)?

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Biogen Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	7500
Exchange	NASDAQ
Company Website	https://www.biogen.com

How to Buy Biogen Inc. (BIIB) Stock on MEXC

Eligible investors can buy real shares of Biogen Inc. (BIIB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for BIIB and Place Your Order

Open the RealStocks trading page and search for BIIB. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Biogen Inc. (BIIB) stock price today?

Biogen Inc. (BIIB) is currently trading at $ 225.63, up 3.30% ($7.20) from the previous close of $ 218.43. Intraday prices update in real time during regular trading hours.

2.Is BIIB stock going up or down today?

As of 2026-10-09 21:08:00, BIIB is trading at $ 225.63, up 3.30% ($7.20) from its previous close of $ 218.43. The stock has traded between $ 5.93 and $ 480.18 during today’s regular session. Past price movements do not guarantee future results.

3.What is BIIB pre-market price?

As of 2026-10-09 21:08:00, BIIB is trading at $ 220.11 in pre-market trading, up 0.77% ($1.67) from the previous close of $ 218.43. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is BIIB after-hours price?

As of 2026-10-09 21:08:00, BIIB is trading at $ 224.08 in after-hours trading, up 2.59% ($5.65) from the regular-session close of $ 218.43. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is BIIB stock trading now?

BIIB trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does BIIB sit relative to its 52-week high and low?

Over the past 52 weeks, BIIB has traded between a low of $ 138.00 and a high of $ 230.49. At $ 225.63, the stock is positioned 94.7% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Biogen Inc. in?

Biogen Inc. (BIIB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Biogen Inc.'s market capitalization and where is it listed?

Biogen Inc. is listed on the NASDAQ exchange with a market capitalization of $ 32.82B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is BIIB valued in terms of P/E ratio and EPS?

BIIB trades at a P/E ratio of 38.67, based on trailing-twelve-month EPS of $ 5.65. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Biogen Inc. pay a dividend?

Biogen Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.